Insilico Medicine
Biotech · AI
Insilico Medicine Inks $2.75B Lilly Deal for AI Oral Drug Candidates
March 29, 2026$2.8B
Insilico Medicine partners with Eli Lilly on commercializing preclinical AI-discovered oral therapeutics, securing $115M upfront and up to $2.75B in milestones. The collaboration targets Lilly-selected indications, including a potential GLP-1 agonist for diabetes.
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.